Skip to main content
Fig. 3 | AIDS Research and Therapy

Fig. 3

From: Real-world adherence and persistence for newly-prescribed HIV treatment: single versus multiple tablet regimen comparison among US medicaid beneficiaries

Fig. 3

Adjusted hazard ratios for risk of treatment discontinuation among treatment cohorts. STR single-tablet regimen, MTR multiple-tablet regimen, 3TC lamivudine, ABC abacavir, ATV atazanavir, ATV/c atazanavir boosted with cobicistat, ATV/r atazanavir boosted with ritonavir, COBI cobicistat, DRV darunavir, DRV/r darunavir boosted with ritonavir, DRV/c darunavir boosted with cobicistat, DTG dolutegravir, EFV efavirenz, EVG elvitegravir, FTC emtricitabine, RPV rilpivirine, TAF tenofovir alafenamide fumarate, TDF tenofovir disoproxil fumarate. ABC/3TC (all), FTC/TAF (all), and FTC/TDF (all) are backbones of STRs and MTRs compared, regardless of their third agents

Back to article page

AIDS Research and Therapy

ISSN: 1742-6405

Contact us